| Severe Combined Immunodeficiency
Flebogamma DIF 5% vs Hizentra
Side-by-side clinical, coverage, and cost comparison for severe combined immunodeficiency.Deep comparison between: Flebogamma vs Hizentra with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsHizentra has a higher rate of injection site reactions vs Flebogamma based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Hizentra but not Flebogamma, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Flebogamma
Hizentra
At A Glance
IV infusion
Every 3-4 weeks
Immune globulin (IGIV)
SC injection
Daily to every 2 weeks
Immune globulin
Indications
- Common Variable Immunodeficiency
- X-linked agammaglobulinemia
- Severe Combined Immunodeficiency
- Wiskott-Aldrich Syndrome
- Primary immune deficiency disorder
- Polyradiculoneuropathy, Chronic Inflammatory Demyelinating
- Wiskott-Aldrich Syndrome
- Common Variable Immunodeficiency
- X-linked agammaglobulinemia
- Severe Combined Immunodeficiency
Dosing
Common Variable Immunodeficiency, X-linked agammaglobulinemia, Severe Combined Immunodeficiency, Wiskott-Aldrich Syndrome 300-600 mg per kg body weight IV every 3-4 weeks; initial infusion rate 0.01 mL/kg/min (0.5 mg/kg/min), increased to maximum 0.10 mL/kg/min (5 mg/kg/min) if tolerated.
Primary immune deficiency disorder, Wiskott-Aldrich Syndrome, Common Variable Immunodeficiency, X-linked agammaglobulinemia, Severe Combined Immunodeficiency Individualized SC dose administered daily to every 2 weeks; when switching from IGIV, initial weekly dose = prior IGIV dose (g) divided by weeks between doses, multiplied by 1.37.
Polyradiculoneuropathy, Chronic Inflammatory Demyelinating 0.2 g/kg (1 mL/kg) SC per week in 1-2 infusion sessions over 1-2 consecutive days; may increase to 0.4 g/kg per week if symptoms worsen on the lower dose.
Contraindications
- History of anaphylactic or severe systemic hypersensitivity reactions to human immune globulin
- IgA-deficient patients with antibodies to IgA and a history of hypersensitivity
- History of anaphylactic or severe systemic reaction to human immune globulin or inactive ingredients of HIZENTRA, including polysorbate 80
- Hyperprolinemia Type I or II (HIZENTRA contains L-proline as stabilizer)
- IgA-deficiency with antibodies against IgA and a history of hypersensitivity
Adverse Reactions
Most common, adults (>=5%) Headache, pyrexia, pain, injection site reactions, diarrhea, rigors, urticaria, infusion site inflammation
Most common, pediatrics (>=5%) Headache, pyrexia, hypotension, tachycardia, diastolic hypotension, nausea, abdominal pain, diarrhea, pain, vomiting
Postmarketing Hypersensitivity/anaphylaxis, acute renal dysfunction/failure, ARDS, TRALI, cardiac arrest, thromboembolism, coma, seizures, aseptic meningitis syndrome, Stevens-Johnson Syndrome, pancytopenia, hemolysis
Most common (>=5%) Local infusion-site reactions (swelling, redness, heat, pain, hematoma, itching), headache, diarrhea, fatigue, back pain, nausea, pain in extremity, cough, upper respiratory tract infection, rash, pruritus, vomiting, abdominal pain, migraine, arthralgia, pain, fall, nasopharyngitis
Postmarketing Allergic-anaphylactic reactions (swollen face or tongue, pharyngeal edema, pyrexia, chills, dizziness, hypertension, malaise, tachycardia, flushing), chest discomfort, dyspnea, tremor, burning sensation, infusion site ulcer, infusion site necrosis
Pharmacology
Flebogamma 5% DIF is an intravenous immune globulin (IGIV) that provides replacement therapy for primary immunodeficiency by supplying a broad spectrum of opsonizing and neutralizing IgG antibodies against a wide variety of bacterial and viral agents.
Immune Globulin Subcutaneous (Human), 20% Liquid that supplies a broad spectrum of opsonizing and neutralizing IgG antibodies against a wide variety of bacterial and viral agents; mechanism of action has not been fully elucidated but may include immunomodulatory effects.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Flebogamma
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (10/12) · Qty limit (0/12)
Hizentra
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (5/12) · Qty limit (0/12)
UnitedHealthcare
Flebogamma
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Hizentra
- Covered on 4 commercial plans
- PA (2/8) · Step Therapy (0/8) · Qty limit (1/8)
Humana
Flebogamma
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (0/3)
Hizentra
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (0/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Flebogamma.
No savings programs available for Hizentra.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
FlebogammaView full Flebogamma profile
HizentraView full Hizentra profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.